Jessalyn M. Ubellacker
Research Subjects
Jessalyn M. Ubellacker has a total of 249 co-authors. Here are the top co-authors by number of shared publications:
- Alpaslan Tasdogan
Department of Dermatology, University Hospital Essen & German Cancer Consortium, Partner Site (DKTK) and Research Alliance Ruhr, Research Center One Health, University Duisburg-Essen, Essen, Germany
55 shared publications - Sean J. Morrison
Children’s Research Institute, University of Texas Southwestern Medical Center
54 shared publications - Luiza Martins Nascentes Melo
Department of Dermatology, University Hospital Essen and German Cancer Consortium (DKTK), Essen, Germany
52 shared publications - Andrea Kutritz
Department of Dermatology, University Hospital Essen & German Cancer Consortium, Essen, Germany
51 shared publications - Gabriele Allies
Department of Dermatology, University Hospital Essen & German Cancer Consortium, Essen, Germany
51 shared publications - Vijayashree Ramesh
Children’s Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, Texas
51 shared publications
Latest Publications
- 1 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (10) , 1967-1972
Studying Ferroptosis in the Tumor Microenvironment
Summary: Despite strong preclinical evidence, ferroptosis-based strategies have not yet translated into the clinic, in part due to the disconnect between conventional in vitro models and the complex tumor microenvironment. In this commentary, we consider ferroptosis as a microenvironmentally regulated process and call for multidisciplinary approaches that bridge foundational ferroptosis biology with clinically actionable interventions grounded in the context of the tumor microenvironment.
- 1 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (10) , 1967-1972
Studying Ferroptosis in the Tumor Microenvironment
Summary: Despite strong preclinical evidence, ferroptosis-based strategies have not yet translated into the clinic, in part due to the disconnect between conventional in vitro models and the complex tumor microenvironment. In this commentary, we consider ferroptosis as a microenvironmentally regulated process and call for multidisciplinary approaches that bridge foundational ferroptosis biology with clinically actionable interventions grounded in the context of the tumor microenvironment.
- 15 September 2026
- Published by Springer Nature in Nature Metabolism
- Vol. 8 (10) , 2048-2050
The high price of ‘free’ cysteine
- 15 September 2026
- Published by Springer Nature in Nature Metabolism
- Vol. 8 (10) , 2048-2050
The high price of ‘free’ cysteine
- 1 September 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (9) , 1730-1738
Insights on Future Directions in Cancer Research from the AACR Trailblazer Cancer Research Grant Awardees
- 1 September 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (9) , 1730-1738
Insights on Future Directions in Cancer Research from the AACR Trailblazer Cancer Research Grant Awardees
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figure 1). TCA cycle labeling and metabolite abundance in tumors and lungs from NSCLC patents.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figure 1). TCA cycle labeling and metabolite abundance in tumors and lungs from NSCLC patents.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figure 3). Overall and recurrence-free survival summary.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figure 3). Overall and recurrence-free survival summary.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figure 2). Transcriptomic data for NSCLC and adjacent lung tissue fragments.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figure 2). Transcriptomic data for NSCLC and adjacent lung tissue fragments.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Selenoprotein O Promotes Melanoma Metastasis and Regulates Mitochondrial Complex II Activity
Supplementary Figure S6 depicts markers of subcellular fractionation used to isolate crude mitochondria.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Selenoprotein O Promotes Melanoma Metastasis and Regulates Mitochondrial Complex II Activity
Supplementary Figure S6 depicts markers of subcellular fractionation used to isolate crude mitochondria.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figure 1). Patient Isotopologue Data.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figure 1). Patient Isotopologue Data.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figure 3). TCA cycle metabolite abundance does not correlate with overall survival.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figure 3). TCA cycle metabolite abundance does not correlate with overall survival.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figure 3). Relationships between TCA cycle labeling and clinical factors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
(Related to Figure 3). Relationships between TCA cycle labeling and clinical factors.